Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
21-12(20)19-11)6-5-8-1-2-8/h3-4
InChiKey: MALFODICFSIXPO-KFKQDBFTSA-N
emodin limits the effect of glucocorticoids and may therefore ameliorate diabetes and insulin resistance
42(5):1822-1836
ethyl ester
Ruxolitinib sulfate - CAS# 1092939-16-6 alog 2 21-12(20)19-11)6-5-8-1-2-8/h3-4Ruxolitinib sulfate is the first potent, selective JAK1 2 inhibitor to enter the clinic with IC50s of 3. 3 nM 2. 8 nM, and has > 130 fold selectivity for JAK1 2 versus JAK3. Ruxolitinib potently and selectively inhibits JAK2V617F mediated signaling and proliferation, markedly increases apoptosis in a dose dependent manner, and at 64 nM results in a doubling of cells with depolarized mitochondria in Ba F3 cells. Ruxolitinib demonstrates remarkable
US$ 4186.12
US$ 43.90
US$ 3041.39